Trial Profile

A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 15 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darovasertib (Primary)
Indications Uveal melanoma
Focus Registrational; Therapeutic Use
Acronyms OptimUM-10
Sponsors IDEAYA Biosciences

Most Recent Events

05 May 2026 According to an IDEAYA Biosciences media release, full enrollment in the trial is estimated to be complete by the end of 2027.
11 Jan 2026 According to an IDEAYA Biosciences media release, complete full enrollment of approximately 450 patients across enucleation and plaque brachytherapy cohorts by H1 '27.
15 Sep 2025 Planned End Date changed from 7 Dec 2027 to 1 Mar 2031.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com